ARTICLE | Management Tracks
Mark Alles at the helm at Torl
Plus: new CSO at Nutcracker, and updates from Asieris, NewAmsterdam, Zura, Capstan and more
January 10, 2024 12:57 AM UTC
Cancer company Torl BioTherapeutics LLC named Mark Alles chairman and CEO, succeeding Dave Licata who will become CFO and continue as president and board member. Alles was chairman and CEO of Celgene Corp.
RNA therapies company Nutcracker Therapeutics Inc. promoted Samuel Deutsch to CSO from EVP of research and early development...